Compare INGN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INGN | HURA |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 160.5M |
| IPO Year | 2013 | N/A |
| Metric | INGN | HURA |
|---|---|---|
| Price | $6.15 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $11.25 | $9.50 |
| AVG Volume (30 Days) | 212.4K | ★ 581.0K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $0.41 |
| 52 Week High | $9.13 | $3.90 |
| Indicator | INGN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 40.23 |
| Support Level | $6.00 | $1.82 |
| Resistance Level | $6.73 | $2.20 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 14.93 | 1.00 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.